Evidence map›Paper›PMID 30077709›Full record

ArticleThe ocular surface2018

Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results.

Valerie Yu, Dhruva Bhattacharya, Andrew Webster, Aditi Bauskar, Charles Flowers, Martin Heur, Shravan K Chintala, Tatsuo Itakura, Mark R Wilson, Joseph T Barr and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The ocular surface, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Clusterin, other extracellular chaperones, and eye disease.Progress in retinal and eye research · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Valerie YuMD Program, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Dhruva BhattacharyaDepartment of Ophthalmology & Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.
Andrew WebsterUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Aditi BauskarPhD Program in Medical Biology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Charles FlowersUSC Roski Eye Institute and Department of Ophthalmology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Martin HeurUSC Roski Eye Institute and Department of Ophthalmology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Shravan K ChintalaUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Tatsuo ItakuraUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Mark R WilsonIllawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, New South Wales, Australia.
Joseph T BarrThe Ohio State University College of Optometry, Columbus, OH, USA.
Shinwu JeongUSC Institute for Genetic Medicine, USC Roski Eye Institute and Department of Ophthalmology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Mingwu WangDepartment of Ophthalmology & Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.
M Elizabeth FiniUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA. Electronic address: mefini@tuftsmedicalcenter.org.
University of Southern California · USUniversity of Arizona · USThe Ohio State University · USUniversity of Wollongong · AU

Funding

Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
Clusterin at the Ocular Surface Administrative Supplement IIR01EY026479 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FINI, M ELIZABETH · 2016 to 2020
$2.9M
NCATS NIH HHS UL1 TR000130NCATS NIH HHS UL1 TR001855NEI NIH HHS R01 EY026479
6 · The paper itself

Abstract

purposeTo investigate the relationship between tear concentration of the homeostatic protein clusterin (CLU) and dry eye signs and symptoms, and to characterize tear CLU protein.

methodsTwo independent studies were conducted, one in Tucson (44 subjects), the other in Los Angeles (52 subjects). A cohort study design was employed to enroll patients without regard to dry eye diagnosis. Dry eye signs and symptoms were assessed using clinical tests. Tear samples were collected by Schirmer strip, and also by micropipette at slit lamp when possible. CLU from both sample types was quantified by immunoassay. The relationship between CLU concentration and clinical test scores was determined by Pearson's correlation coefficient (for individual eyes) and multiple linear regression analysis (including both eyes). CLU was also evaluated biochemically by western blotting.

resultsIn the Tucson cohort, a positive correlation was observed between tear CLU concentration and results of the Schirmer strip test, a measure of tear flow (p = 0.021 includes both eyes). This result was corroborated in the Los Angeles cohort (p = 0.013). The mean tear CLU concentration was 31 ± 14 μg/mL (n = 18 subjects, 33 eyes; range = 7-48 μg/mL). CLU from clinical tear samples appeared biochemically similar to CLU from a non-clinical tear sample and from blood plasma.

conclusionsResults support the hypothesis that an optimal concentration of tear CLU is important for ocular surface health, and that this drops below the effective threshold in dry eye. Tear CLU measurement might identify patients that could benefit from supplementation. Information about concentration will aid development of therapeutic dosage parameters.

Indexed as

AdultAgedAged, 80 and overClusterinCohort StudiesDry Eye SyndromesFemaleHumansMaleMiddle AgedRegression AnalysisTearsCLU protein, humanClusterinClusterinDry eyeMMP inhibitorMolecular chaperoneOcular surface diseaseSchirmer testTears

Identifiers

PMID30077709
PMCPMC6175631
OpenAlexW2887975697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.